Myriad Genetics (MYGN) Advances in MRD Space With New Patent
Myriad(MYGN) ZACKS·2024-07-10 20:56
Myriad Genetics, Inc. (MYGN) recently secured a second foundational patent from the United States Patent and Trademark Office that bolsters its abilities to launch a tumor-informed, high-definition, molecular residual disease (MRD) assay. U.S. patent no. 12,024,749, entitled “Combinatorial DNA Screening,” covers the company’s breakthrough platform MRD technology, which enables highly sensitive and specific tumor-informed, sequencing-based MRD assays such as Precise MRD.The latest development reveals another ...